세계의 멀티오믹스 시장 : 제품?서비스별, 적응증별, 용도별, 최종 사용자별 예측(2025-2030년)

The Metabolomics Market was valued at USD 3.74 billion in 2023, expected to reach USD 4.28 billion in 2024, and is projected to grow at a CAGR of 15.06%, to USD 9.99 billion by 2030.

Metabolomics, a comprehensive study of metabolites within a biological specimen, serves as a pivotal tool in understanding the intricate biochemical processes of living organisms. This field is critical for advancements in personalized medicine, disease biomarker discovery, and systems biology. Its application spans pharmaceuticals, biotechnology, agrigenomics, and food & beverages, among other sectors, making it an indispensable asset for innovation in health and nutrition. Key factors influencing the metabolomics market's growth include technological advancements in analytical techniques, increasing pharmaceutical and biotech R&D investments, and the rising prevalence of chronic diseases necessitating enhanced diagnostic methodologies. Recent technological innovations in mass spectrometry and nuclear magnetic resonance, coupled with advancements in bioinformatics, present significant opportunities for early disease detection and precision medicine development. However, challenges such as high costs of instruments and the need for skilled personnel may hinder market growth. There is also a notable requirement for standardization in methodologies and data interpretation to bridge the gap between complex data outputs and practical applications. Despite these concerns, regions like North America and Europe are leading metabolomics innovations due to supportive regulatory frameworks and substantial healthcare spending. To capitalize on this growing market, businesses should focus on expanding collaborative networks between academic institutions and industry players to spur technological development and knowledge exchange. Additionally, the development of cost-effective, high-throughput screening methods could transform metabolite analysis accessibility and application in various industries. Exploring novel areas such as microbiome metabolomics, plant metabolomics, and environmental metabolomics holds promise for new product development and diversification. The ever-evolving nature of the metabolomics market suggests a fertile ground for research and innovation, necessitating organizations to stay abreast of technological advancements and policy changes to optimize their strategy for sustained growth and competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Metabolomics Market

The Metabolomics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of cancer cases and need for advanced therapies
  • Ongoing adoption of personalized medicines
  • Favorable governmental initiatives associated with metabolomics research
• Market Restraints
  • Concern regarding the complex data monitoring and data processing
• Market Opportunities
  • Emergence of novel technologies along with market players for metabolomics
  • Rise of single-cell metabolomics
• Market Challenges
  • Scarcity of skilled professionals in the healthcare sectors worldwide

Porter's Five Forces: A Strategic Tool for Navigating the Metabolomics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Metabolomics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Metabolomics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Metabolomics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Metabolomics Market

A detailed market share analysis in the Metabolomics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Metabolomics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Metabolomics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Metabolomics Market

A strategic analysis of the Metabolomics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Metabolomics Market, highlighting leading vendors and their innovative profiles. These include Afekta Technologies Ltd., Bio-Rad Laboratories, Inc., Biocrates Life Science AG, Bruker Corporation, Danaher Corporation, General Electric Company, Hitachi High-Tech Corporation, Human Metabolome Technologies America Inc., Japan Spectroscopic Company, Kore Technology Limited, LECO Corporation, Merck KGaA, SCION Instruments UK Ltd, Shimadzu Corporation, and Waters Corporation.

Market Segmentation & Coverage

This research report categorizes the Metabolomics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product & Service, market is studied across Bioinformatics Tools & Services and Metabolomics Instruments. The Bioinformatics Tools & Services is further studied across Bioinformatics Services and Bioinformatics Tools & Databases. The Metabolomics Instruments is further studied across Detection Tools and Separation Tools. The Detection Tools is further studied across Mass Spectrometry, Nuclear Magnetic Resonance Spectroscopy, and Surface-Based Mass Analysis. The Separation Tools is further studied across Capillary Electrophoresis, Gas Chromatography, High-performance Liquid Chromatography, and Ultra-performance Liquid Chromatography.
• Based on Indication, market is studied across Cancer, Cardiovascular Disorders, Inborn Errors of Metabolism, Metabolic Disorders, and Neurological Disorders.
• Based on Application, market is studied across Biomarker discovery, Drug discovery, Functional Genomics, Nutrigenomics, Personalized medicine, and Toxicology testing.
• Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of cancer cases and need for advanced therapies
    • 5.1.1.2. Ongoing adoption of personalized medicines
    • 5.1.1.3. Favorable governmental initiatives associated with metabolomics research
  • 5.1.2. Restraints
    • 5.1.2.1. Concern regarding the complex data monitoring and data processing
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of novel technologies along with market players for metabolomics
    • 5.1.3.2. Rise of single-cell metabolomics
  • 5.1.4. Challenges
    • 5.1.4.1. Scarcity of skilled professionals in the healthcare sectors worldwide
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Metabolomics Market, by Product & Service

• 6.1. Introduction
• 6.2. Bioinformatics Tools & Services
  • 6.2.1. Bioinformatics Services
  • 6.2.2. Bioinformatics Tools & Databases
• 6.3. Metabolomics Instruments
  • 6.3.1. Detection Tools
    • 6.3.1.1. Mass Spectrometry
    • 6.3.1.2. Nuclear Magnetic Resonance Spectroscopy
    • 6.3.1.3. Surface-Based Mass Analysis
  • 6.3.2. Separation Tools
    • 6.3.2.1. Capillary Electrophoresis
    • 6.3.2.2. Gas Chromatography
    • 6.3.2.3. High-performance Liquid Chromatography
    • 6.3.2.4. Ultra-performance Liquid Chromatography

7. Metabolomics Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Cardiovascular Disorders
• 7.4. Inborn Errors of Metabolism
• 7.5. Metabolic Disorders
• 7.6. Neurological Disorders

8. Metabolomics Market, by Application

• 8.1. Introduction
• 8.2. Biomarker discovery
• 8.3. Drug discovery
• 8.4. Functional Genomics
• 8.5. Nutrigenomics
• 8.6. Personalized medicine
• 8.7. Toxicology testing

9. Metabolomics Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Metabolomics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Metabolomics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Metabolomics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Afekta Technologies Ltd.
• 2. Bio-Rad Laboratories, Inc.
• 3. Biocrates Life Science AG
• 4. Bruker Corporation
• 5. Danaher Corporation
• 6. General Electric Company
• 7. Hitachi High-Tech Corporation
• 8. Human Metabolome Technologies America Inc.
• 9. Japan Spectroscopic Company
• 10. Kore Technology Limited
• 11. LECO Corporation
• 12. Merck KGaA
• 13. SCION Instruments UK Ltd
• 14. Shimadzu Corporation
• 15. Waters Corporation